PharmaCorp Rx Inc.
PCRX.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 809.70K | 213.00K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 809.70K | 213.00K | -- | -- | -- |
| Cost of Revenue | 505.20K | 140.90K | -- | -- | -- |
| Gross Profit | 304.60K | 72.10K | -- | -- | -- |
| SG&A Expenses | 1.07M | 497.80K | 167.70K | 178.10K | 96.60K |
| Depreciation & Amortization | 55.60K | 16.40K | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.63M | 655.10K | 167.70K | 178.10K | 96.60K |
| Operating Income | -817.80K | -442.10K | -167.70K | -178.10K | -96.60K |
| Income Before Tax | -716.20K | -434.30K | -150.20K | -158.90K | -75.20K |
| Income Tax Expenses | 600.00 | -200.00 | -- | -- | -- |
| Earnings from Continuing Operations | -716.80K | -434.20K | -150.20K | -158.90K | -75.20K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.30K | -1.20K | -- | -- | -- |
| Net Income | -715.50K | -435.40K | -150.20K | -158.90K | -75.20K |
| EBIT | -817.80K | -442.10K | -167.70K | -178.10K | -96.60K |
| EBITDA | -780.80K | -433.90K | -- | -- | -- |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 113.16M | 55.64M | 20.28M | 20.28M | 20.28M |
| Average Diluted Shares Outstanding | 113.16M | 55.64M | 20.28M | 20.28M | 20.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
